Sharing innovation to inspire action

New therapy for those suffering Rheumatoid Arthritis

post-image
Global research-based biopharmaceutical company AbbVie has announced U.S FDA approval for their new therapy for adults with moderately to severely active rheumatoid arthritis (RA). RINVOQ is a once-daily (15mg) oral Janus kinase inhibitor supported by data from the SELECT program - one of the largest registrational Phase 3 programs in RA. Approximately 4,400 patients were evaluated across all treatment arms in five studies. The company says that RINVOQ has the potential to help additional people living with RA achieve remission who have not yet reached this goal. https://urlzs.com/SxYV2
What do you think?

You must be logged in to post a comment.
Comments
Generic placeholder image

By Mel Raassina

23 August 2019

 
2 Like


Related Posts

Healthcare

post-image

Grapes - an edible sunscreen
24 February 2021 by Jenny Morawsk... 0 Comments
 
2 Like

Healthcare

post-image

Copper is the New Silver
22 February 2021 by Jeremy Ungar 0 Comments
 
1 Like

Healthcare

post-image

A weight loss drug repurposed to save lives
16 February 2021 by Lynn Wood 1 Comments
 
1 Like